Is Adicet Bio Stock a Good Investment?
Adicet Bio Investment Advice | ACET |
- Examine Adicet Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Adicet Bio's leadership team and their track record. Good management can help Adicet Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Adicet Bio's business and its evolving consumer preferences.
- Compare Adicet Bio's performance and market position to its competitors. Analyze how Adicet Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Adicet Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Adicet Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Adicet Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Adicet Bio is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Adicet Bio Stock
Researching Adicet Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adicet Bio has Price/Earnings To Growth (PEG) ratio of 0.82. The entity recorded a loss per share of 1.7. The firm last dividend was issued on the 16th of September 2020. Adicet Bio had 1:7 split on the 16th of September 2020.
To determine if Adicet Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adicet Bio's research are outlined below:
| Adicet Bio generated a negative expected return over the last 90 days | |
| Adicet Bio has some characteristics of a very speculative penny stock | |
| Adicet Bio has high historical volatility and very poor performance | |
| Adicet Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (142.66 M) with profit before overhead, payroll, taxes, and interest of 24.99 M. | |
| Adicet Bio currently holds about 260.64 M in cash with (93.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635 |
Adicet Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adicet Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adicet Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Adicet Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Adicet Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.39 | -0.35 | 0.04 | 10 | ||
2016-06-30 | 2016-06-30 | 0.39 | 0.35 | -0.04 | 10 | ||
2022-03-15 | 2021-12-31 | -0.42 | -0.47 | -0.05 | 11 | ||
2023-08-09 | 2023-06-30 | -0.68 | -0.75 | -0.07 | 10 | ||
2022-08-10 | 2022-06-30 | -0.45 | -0.56 | -0.11 | 24 | ||
2017-08-24 | 2017-06-30 | 0.44 | 0.27 | -0.17 | 38 | ||
2021-08-12 | 2021-06-30 | -0.53 | -0.34 | 0.19 | 35 | ||
2022-05-12 | 2022-03-31 | -0.18 | 0.1 | 0.28 | 155 |
Know Adicet Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adicet Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adicet Bio backward and forwards among themselves. Adicet Bio's institutional investor refers to the entity that pools money to purchase Adicet Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 917.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 851.6 K | Geode Capital Management, Llc | 2024-09-30 | 768.6 K | Two Sigma Advisers, Llc | 2024-09-30 | 706.6 K | Two Sigma Investments Llc | 2024-09-30 | 703.4 K | Alyeska Investment Group, L.p. | 2024-09-30 | 655.7 K | Stonepine Capital Management Llc | 2024-09-30 | 609.4 K | Rbf Llc | 2024-09-30 | 601.1 K | Dafna Capital Management Llc | 2024-09-30 | 600 K | Orbimed Advisors, Llc | 2024-09-30 | 11.4 M | Tang Capital Management Llc | 2024-09-30 | 8.2 M |
Adicet Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 90.64 M.Market Cap |
|
Adicet Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.65) | |
| Return On Capital Employed | (0.81) | (0.77) | |
| Return On Assets | (0.69) | (0.65) | |
| Return On Equity | (0.84) | (0.80) |
Determining Adicet Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Adicet Bio is a good buy. For example, gross profit margin measures Adicet Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adicet Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Adicet Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adicet Bio. Check Adicet Bio's Beneish M Score to see the likelihood of Adicet Bio's management manipulating its earnings.
Evaluate Adicet Bio's management efficiency
Adicet Bio has return on total asset (ROA) of (0.293) % which means that it has lost $0.293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5791) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.77 in 2024. Total Current Liabilities is likely to drop to about 18.3 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 165.2 M in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.95 | 7.44 | |
| Tangible Book Value Per Share | 3.95 | 2.75 | |
| Enterprise Value Over EBITDA | 0.42 | 0.44 | |
| Price Book Value Ratio | 0.48 | 0.45 | |
| Enterprise Value Multiple | 0.42 | 0.44 | |
| Price Fair Value | 0.48 | 0.45 | |
| Enterprise Value | -57.4 M | -54.6 M |
Adicet Bio benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 1.698 |
Basic technical analysis of Adicet Stock
As of the 4th of December, Adicet Bio shows the Standard Deviation of 4.04, risk adjusted performance of (0.06), and Mean Deviation of 2.94. Adicet Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Adicet Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adicet Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schor Chen over two months ago Acquisition by Schor Chen of 421600 shares of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Disposition of 26400 shares by Aya Jakobovits of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Acquisition by Aya Jakobovits of 5900 shares of Adicet Bio subject to Rule 16b-3 | ||
Sanna Bastiano over six months ago Disposition of 28828 shares by Sanna Bastiano of Adicet Bio at 12.0 subject to Rule 16b-3 | ||
Schor Chen over a year ago Acquisition by Schor Chen of 240000 shares of Adicet Bio subject to Rule 16b-3 | ||
Schor Chen over a year ago Sale by Schor Chen of 5500 shares of Adicet Bio | ||
Silverstein Jonathan over a year ago Conversion by Silverstein Jonathan of 2425482 shares of Adicet Bio | ||
Schor Chen over a year ago Bona fide gift to Schor Chen of 26712 shares of Adicet Bio subject to Section 16 |
Adicet Bio's Outstanding Corporate Bonds
Adicet Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adicet Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adicet bonds can be classified according to their maturity, which is the date when Adicet Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Adicet Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Adicet Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 2.94 | |||
| Coefficient Of Variation | (1,183) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.36 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 16.52 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 6.43 | |||
| Skewness | 0.8063 | |||
| Kurtosis | 2.8 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 2.94 | |||
| Coefficient Of Variation | (1,183) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.36 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 16.52 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 6.43 | |||
| Skewness | 0.8063 | |||
| Kurtosis | 2.8 |
Consider Adicet Bio's intraday indicators
Adicet Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adicet Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Adicet Bio time-series forecasting models is one of many Adicet Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adicet Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Adicet Stock media impact
Far too much social signal, news, headlines, and media speculation about Adicet Bio that are available to investors today. That information is available publicly through Adicet media outlets and privately through word of mouth or via Adicet internal channels. However, regardless of the origin, that massive amount of Adicet data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Adicet Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Adicet Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Adicet Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Adicet Bio alpha.
Adicet Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Adicet Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adicet Bio Corporate Management
| Francesco MD | Chief VP | Profile | |
| BA CPA | Pres CEO | Profile | |
| Blake Aftab | Senior Officer | Profile | |
| Donald Healey | Chief Officer | Profile | |
| Amy Locke | Head Resources | Profile | |
| Brian Harvey | Chief Officer | Profile | |
| Aya Jakobovits | Founder Director | Profile |
Already Invested in Adicet Bio?
The danger of trading Adicet Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adicet Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adicet Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adicet Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.